PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial
Conditions: Glioma; Glioma, Malignant; Recurrent Glioma Interventions: Radiation: PRDR Sponsors: Baptist Health South Florida; Ion Beam Applications SA Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 3, 2024 Category: Research Source Type: clinical trials
Clinical Study of Allogeneic V γ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma
Conditions: GBM; DIPG Brain Tumor; Medulloblastoma Interventions: Biological: V γ9Vδ2 T cell Sponsors: Beijing Tiantan Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 2, 2024 Category: Research Source Type: clinical trials
Advanced Development of Desorption Electrospray Ionization Mass Spectrometry for Intraoperative Molecular Diagnosis of Brain Cancer Using Pathology Biopsies
Conditions: Glioma Interventions: Other: Non-Interventional Study Sponsors: Mayo Clinic; National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 29, 2024 Category: Research Source Type: clinical trials
Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life
Conditions: Glioma; Glioma, Malignant Interventions: Diagnostic Test: Resting State Functional Magnetic Resonance Imaging (rs-fMRI); Behavioral: Up-front Motor Rehabilitation; Drug: Up-front Chemotherapy Sponsors: University of Milan; University of Turin, Italy Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas
Conditions: Low-grade Glioma Interventions: Drug: Tovorafenib Sponsors: Daniel Morgenstern; The Hospital for Sick Children Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
FIH Clinical Investigation of Graphene Electrodes for Brain Mapping
Conditions: Brain Tumor; Glioma Interventions: Device: INBRAIN Graphene Cortical Interface Sponsors: University of Manchester; Northern Care Alliance NHS Foundation Trust; European Commission; Inbrain Neuroelectronics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
Sub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma
Conditions: Glioma; Glioblastoma Interventions: Procedure: sub-lobectomy; Procedure: imaging total resection Sponsors: Huashan Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
TLX101-CDx (Pixclara) Granted FDA Fast Track Designation
Melbourne (Australia) | 16 April 2024 -- Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation1 for the Company’s investigational glioma imaging product, TLX101-CDx... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 16, 2024 Category: Pharmaceuticals Source Type: clinical trials
Evaluate the Effectiveness and Safety of Raman IVD Analyzer in the Molecular Diagnosis of Gliomas During Surgery
Conditions: Glioma Interventions: Diagnostic Test: Immunohistochemistry or genetic test Sponsors: Beijing Tiantan Hospital; West China Hospital; The First Affiliated Hospital of Zhengzhou University; Capital Medical University; Jiangsu Raman Medical Equipment Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
IL13R α2 CAR-T for Patients With r/r Glioma
Conditions: Glioma Interventions: Biological: IL13R α2 CAR-T Sponsors: Yang Zhang; TCRCure Biopharma Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
Conditions: Pediatric Tumor of CNS; Pediatric Tumor of Brain; Diffuse Midline Glioma, H3 K27M-Mutant; Pediatric Tumor of Brain Stem; Pineocytoma; Choroid Plexus Carcinoma, Childhood; Spinal Cord Tumor; High Grade Glioma Interventions: Drug: NEO100 Sponsors: Neonc Technologies, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness
Conditions: Glioblastoma; Glioma; Glioma Glioblastoma Multiforme Interventions: Other: cell isolation from tumor biopsies and biomarker investigation Sponsors: Fondazione IRCCS Ca ' Granda, Ospedale Maggiore Policlinico Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
Conditions: Astrocytoma; Glioma; Recurrent Glioblastoma Interventions: Radiation: Radiation Therapy Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma
Conditions: Diffuse Hemispheric Glioma, H3 G34-Mutant Interventions: Procedure: Biospecimen Collection; Biological: Dendritic Cell Therapy; Procedure: Leukapheresis; Procedure: Magnetic Resonance Imaging; Drug: Poly ICLC Sponsors: Jonsson Comprehensive Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Conditions: High Grade Glioma; Diffuse Intrinsic Pontine Glioma; Anaplastic Astrocytoma; Infant Type Hemispheric Glioma; Glioblastoma; Glioblastoma Multiforme; WHO Grade III Glioma; WHO Grade IV Glioma; Diffuse Midline Glioma, H3K27-altered Interventions: Drug: Lorlatinib; Drug: Lorlatinib with chemotherapy1; Drug: Lorlatinib with chemotherapy 2; Drug: Lorlatinib post Radiation Sponsors: Nationwide Children ' s Hospital; Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
